Institut National De La Sante Et De La Recherche Medicale

Universitè De Montpellier

Centre National De La Recherche Scientifique

UniversitÉde Strasbourg

Université Montpellier 2 Sciences Et Techniques

Biodol Therapeutics

Inserm (institut National De La Sante Et De La Recherche Medicale)

Jean Valmier

Didier Rognan

Martine Schmitt

Jean-Philippe Leyris

The present invention relates to FLT3 receptor antagonists or inhibitors of FLT3 receptor gene expression for the treatment or the prevention of pain disorders.

FLT3 receptor antagonists for the treatment or the prevention of pain disorders

The present invention relates to FLT3 receptor inhibitor for use in the treatment of neuropathic pain and chronic pain comprising a neuropathic component, wherein the daily dosage range per human adult per day of said FLT3 receptor inhibitor consists of a dosage range determined by a method comprising the steps of: (i) determining the minimal inhibiting dose of said FLT3 receptor inhibitor that induces the maximal inhibition of mechanical pain hypersensitivity, (ii) converting said dose to the Human Equivalent Dose (HED) by the allometric correction method, and (iii) establishing a daily dosage range per human adult per day wherein (iii-1) the lower limit of the said daily dosage range per human adult per day is the greater value between HED/20 determined via a rat model and 0.001 mg, and (iii-2) the upper limit of the said daily dosage range is the lower value between HED*20 determined via a rat model and 50 mg.

FLT3 receptor inhibitor at low dosage for the treatment of neuropathic pain

The invention pertains to novel FLT3 receptor antagonists of general formula (1). The compounds are useful for the treatment or the prevention of pain disorders, cancer and autoimmune diseases. 

FLT3 receptor antagonists

Growing community of inventors

Montpellier, France

Jean Valmier